The present invention relates to the field of medical electronics. In particular, it concerns electronic systems, devices, and methods for acquisition, processing, and presentation of diagnostic data for use with humans and animals, such as electrocardiogram data.
Although the electrocardiogram (frequently referred to as “ECG” or “EKG”) is a universally accepted diagnostic method in cardiology, frequent mistakes are made in interpreting ECGs, because the most common approach for interpretation of ECGs is based on human memorization of waveforms, rather than using vector concepts and basic principles of electrocardiography (see Hurst, J. W., Clin. Cardiol. 2000 January; 23(1):4-13). Another problem with traditional ECG recordings is that the ECG may not provide adequate indications of electrical activity of certain regions of the heart, especially the posterior region. The timing of cardiac electrical events, and the time intervals between two or more such events, has diagnostic and clinical importance. However, medical diagnosis and drug development has been significantly limited by the lack of adequate ECG measurement tools. Furthermore, prior analysis of ECG recordings required a substantial amount of training and familiarity with reading of the recorded waveforms. There have been many attempts to extract additional information from the standard 12-lead ECG measurement when measuring the electric potential distribution on the surface of the patient's body for diagnostic purposes. These attempts have included new methods of measured signal interpretation, either with or without introducing new measurement points, in addition to the standard 12-lead ECG points.
One of the oldest approaches, vector ECG (or “VCG”) includes the improvement of a spatial aspect to the ECG (see Frank, E., An Accurate, Clinically Practical System For Spatial Vectorcardiography, Circulation 13: 737, May 1956). Like conventional ECG interpretation, VCG uses a dipole approximation of electrical heart activity. The dipole size and orientation are presented by a vector that continuously changes during the heartbeat cycle. Instead of presenting signal waveforms from the measurement points (waveforms), as it is the case with standard 12-lead ECGs, in VCG, the measurement points are positioned in such a way that three derived signals correspond to three orthogonal axes (X, Y, Z), and these signals are presented as projections of the vector hodograph onto three planes (frontal, sagittal, and horizontal). In this way, VCG represents a step towards spatial presentation of the signal, but the cardiologist's spatial imagination skills were still necessary to interpret the ECO signals, particularly the connection to the heart anatomy. Furthermore, a time-dependence aspect (i.e., the signal waveform) is lost with this procedure, and this aspect is very important for ECG interpretation. VCG introduces useful elements which cannot be found within the standard 12-lead ECG, however, the incomplete spatial presentation and loss of the time dependence are major reasons why VCG, unlike ECG, has never been widely adopted, despite the fact that (in comparison to ECG) VCG can more often correctly diagnose cardiac problems, such as myocardial infarction.
There have been numerous attempts to overcome the drawbacks of the VCG method described above. These methods exploit the same signals as VCG (X, Y, Z), but their signal presentation is different than the VCG projection of the vector hodograph onto three planes. “Polarcardiogram” uses Aitoff cartographic projections for the presentation of the three-dimensional vector hodographs (see Sada, T., et al., J. Electrocardiol. 1982; 15(3):259-64). “Spherocardiogram” adds information on the vector amplitude to the Aitoff projections, by drawing circles of variable radius (see Niederberger, M., et al., J. Electrocardiol. 1977; 10(4):341-6). “3D VCG” projects the hodograph onto one plane (see Morikawa, J., et al., Angiology, 1987; 38(6):449-56. “Four-dimensional ECG” is similar to “3D VCG,” but differs in that every heartbeat cycle is presented as a separate loop, where the time variable is superimposed on one of the spatial variables (see Morikawa, J., et al., Angiology, 1996; 47: 1101-6.). “Chronotopocardiogram” displays a series of heart-activity time maps projected onto a sphere (see Titomir, L. I., et al., Int J Biomed Comput 1987; 20(4):275-82). None of these modifications of VCG have been widely accepted in diagnostics, although they have some improvements over VCG.
Electrocardiographic mapping is based on measuring signals from a number of measurement points on the patient's body. Signals are presented as maps of equipotential lines on the patient's torso (see McMechan, S. R., et al., J. Electrocardiol. 1995; 28 Suppl:184-90). This method provides significant information on the spatial dependence of electrocardiographic signals. The drawback of this method, however, is a prolonged measurement procedure in comparison to ECG, and a loose connection between the body potential map and heart anatomy.
Inverse epicardiac mapping includes different methods, all of which use the same signals for input data as those used in ECG mapping; and they are all based on numerically solving the so-called inverse problem of electrocardiography (see A. van Oosterom, Biomedizinisch Technik., vol. 42-El, pp. 33-36, 1997). As a result, distributions of the electric potentials on the heart are obtained. These methods have not resulted in useful clinical devices.
Cardiac electrical activity can be detected at the body surface using an electrocardiograph, the most common manifestation of which is the standard 12-lead ECG. Typical ECG signals are shown in present
Physiologically, the Twave is the ECG manifestation of repolarization gradients, that is, disparities in degree of repolarization at a particular time point between different regions of the heart. It is likely that the Twave originates primarily from transmural repolarization gradient (see Yan and Antzelevitch; Circulation 1998; 98:1928-1936; Antzelevitch, J. Cardiovasc Electrophysiol 2003; 14:1259-1272.) Apico-basal and anteriorposterior repolarization gradients may also contribute (see Cohen I S, Giles W R, and Noble D; Nature. 1976; 262:657-661).
Transmural repolarization gradients arise because the heart's outer layer (epicardium) repolarizes quickly, the mid-myocardium repolarizes slowly, and the inner layer (endocardium) repolarizes in intermediate fashion. Referring again to
Finally, the M cells repolarize, accounting for the latter part of the Twave downslope. The Twave is complete at Tend (8) when all layers are at resting potential and the transmural gradient is abolished.
The QT interval (9) may be estimated from an ECG by measuring time from the end of the PR segment (5) to Tend (8). Abnormalities in the QT interval often mark susceptibility to life-threatening arrhythmias. Such abnormalities may be associated with genetic abnormalities, various acquired cardiac abnormalities, electrolyte abnormalities, and certain prescription and nonprescription drugs. An increasing number of drugs have been shown to prolong the QT interval and have been implicated as causes of arrhythmia. As a result, drug regulatory agencies are conducting increasingly detailed review of drug-induced abnormalities in cardiac electrical activity. The accuracy and precision of individual measurements is highly important for clinical diagnosis of heart disease and for evaluation of drug safety. Drug regulatory bodies worldwide now require detailed information regarding drug effects on cardiac intervals measured from ECG data (see M. Malik, PACE 2004; 27:1659-1669; Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs, http://www.fda.gov/cder/guidance/6922fnl.pdf).
Improved measurement accuracy and precision would reduce the risk of clinical error and the amount of resources required during drug development to meet regulatory requirements. This is particularly true for QT interval measurement. Problems in manual QT interval determination result in part from lead selection. Measured QT intervals can vary significantly depending upon the ECG lead selected for measurement. Another common problem is finding Tend. This is usually defined as the point at which the measured voltage returns to the isoelectric baseline. However, Twaves are often low-amplitude, morphologically abnormal, fused with a following U-wave, or obscured by noise. The same may apply to J-points, P-waves, U-waves and other important cardiac events.
Another fairly fundamental and important issue lies with selecting what data analyze. For example, it is convention in many hospitals and clinical study venues to utilize any three consecutive beats (from one ECG lead) from three successive ECG readings taken within a two minute time period. The challenge with such paradigm is that such data may or may not accurately represent the entire population of ECG signal activity for that particular patient. With the advent of Holter type monitors, more data is available, but in many clinical study settings, all of the data collected is not analyzed; rather, only selective portions of the data are examined, in accordance with whatever clinical study data analysis protocol is in place.
Referring to
Accurate and reproducible procedures for cardiac interval measurement are urgently needed. In particular, it would be valuable to have techniques and systems that involve less human subjective judgement, and take better advantage of the voluminous data available from modern collection systems, such as Holter type ECG collection systems. The subject invention addresses this challenge with a relatively noise-tolerant solution for determining the timing of cardiac electrical events.
One embodiment of the invention is directed to a method for processing ECG data acquired during an acquisition window time period, comprising: selecting a scanning window time period less than or equal to the acquisition time period; selecting a stability analysis window time period less than or equal to the scanning window time period; selecting an extraction window time period less than the stability analysis window time period; calculating a confidence factor for each beat comprising the ECG acquired during the scanning window time period; filtering out nonusable beats based upon the calculated confidence factors and a predetermined confidence threshold to arrive at a set of remaining usable beat data; conducting moving window stability analysis on stability windows of the usable beat ECG data, the stability windows defined by the stability analysis window time period, to numerically rank the stability windows in terms of stability; and extracting representative ECG data from a plurality of the best ranking, nonoverlapping, stability windows based upon extraction window positions within the stability windows defined by the extraction window time period. The scanning window time period may be about 10 minutes. The stability analysis window time period may be about 30 seconds, 60 sec, 90 sec, 120 sec, or any other arbitrary time period that is greater than the extraction window and less than the scanning window. The extraction window time period may be about 10 seconds, 20 sec, 30 sec, or any other arbitrary time period that is less than or equal to the chosen stability analysis window time period. Calculating a confidence factor may comprise establishing a confidence score based upon one or more factors selected from the group consisting of: an ECG signal confirmation factor, a noise level factor, and a curve fitting quality of measurement factor. The confidence factor may be expressed conveniently as a number between 0 and 100, and a predetermined confidence factor threshold may be about 0, 10, 20, 30, 40, 50, 60, 70, 80 or any number on the scale of 0 to 100, according to the discretion of the user. Conducting moving window stability analysis on stability windows of the usable beat ECG data may comprise creating a plurality of temporally adjacent and overlapping stability window datasets, and conducting a formula-based numerical stability analysis of beats captured within each of the plurality of stability window datasets. Conducting a formula-based numerical stability analysis may comprise calculating a plurality of IDMs (for example, RR, PR, QRS, or QT intervals, and the like) for each beat of the usable beat ECG data residing in each of the plurality of stability window datasets. Conducting a formula-based numerical stability analysis may further comprise calculating a standard deviation of IDMs (for example, RR, PR, QRS, or QT intervals, and the like) for all usable beat ECG data residing in each of the plurality of stability window datasets. Conducting a formula-based numerical stability analysis may further comprise calculating an IDM distance rank (for example, distance rank for RR, PR, QRS, or QT intervals, and the like) based upon the difference between a calculated average IDM value for a given stability window dataset relative to a mean or median IDM value for all usable beat ECG data residing within the entire scanning window time period. Conducting a formula-based numerical stability analysis may further comprise calculating a standard deviation of RR time values for all usable beats in each stability window dataset. Conducting a formula-based numerical stability analysis may further comprise calculating the number of usable beats in each stability window dataset. Representative ECG data may be extracted from the three best ranking stability windows, which are preferably nonoverlapping. The method may further comprise conducting statistical analysis based upon the extracted ECG data to determine what factors are responsible for variance in the ECG data in a population of patients. Statistical analysis may be conducted to determine whether a medicinal treatment is statistically responsible for variance in the ECG data in a population of patients, some of whom have been exposed to such medicinal treatment.
Another embodiment is directed to a system for processing ECG data acquired during an acquisition window time period, comprising a memory device configured to store data pertinent to one or more ECG signal waves sampled from electrodes operably coupled to one or more cardiac tissue structures during an acquisition window time period; and a processor operably coupled to the memory device and configured to controllably access the data, the processor configured to allow an operator to select a scanning window time period less than or equal to the acquisition time period, a stability analysis window time period less than or equal to the scanning window time period, and an extraction window time period less than the stability analysis window time period; calculate a confidence factor for each beat comprising the ECG acquired during the scanning window time period; filter out nonusable beats based upon the calculated confidence factors and a predetermined confidence threshold to arrive at a set of remaining usable beat data; conduct moving window stability analysis on stability windows of the usable beat ECG data, the stability windows defined by the stability analysis window time period, to numerically rank the stability windows in terms of stability; and extract representative ECG data from a plurality of the best ranking, nonoverlapping, stability windows based upon extraction window positions within the stability windows defined by the extraction window time period. The processor and memory device may be operably coupled to an analog signal acquisition system. The analog signal acquisition system may be operably coupled to one or more cardiac electrodes. The processor and memory device may be enclosed within an implantable housing. The implantable housing may be operably coupled to an external computing system and configured to exchange data with the external computing system by wire, or wirelessly. The analog signal acquisition system may comprise an ambulatory Holter monitor.
Referring to
Referring to
Subsequent to filtering to create the subset of usable beat data, moving window stability analysis may be conducted on the usable beat dataset to numerically rank each of the stability windows in terms of data stability (40). In one embodiment, a simple formula may be utilized to create an overall stability score for each stability window:
Stability Rank=M*(StdDev(QTc) rank)+N*(QTc distance rank)+O*(StdDev(RR) rank)+P*(number of beats rank)
In the above formula, “StdDev(QTc)” represents the standard deviation of corrected QT interval values of all usable beats in a given stability window; the window having the lowest StdDev(QTc) will get the lowest (best) rank. “Corrected QT interval values”, “Corrected QT”, and “QTc” are all used interchangeably to mean the measured QT interval value corrected for heart rate, for example by Bazett's formula (QTc=QT/(RR)0.5, Fridercia's formula (QTc=QT/(RR)0.33, or individualized rate correction, the application of which are well known to those of ordinary skill in the art. In the above formula, “QTc distance” is a rank based on the difference between an average (mean or median) QTc value for the stability window and the mean or median QTc value of all usable beats within a given scanning window. The stability window having the shortest distance (smallest difference) from such mean or median value shall be assigned the lowest (best) rank. In the above formula, “StdDev(RR)” represents the standard deviation of RR interval values of all usable beats in a given stability window. The window having the lowest StdDev(RR) is assigned the lowest (best) rank. In the above formula, the “number of beats rank” simply represents the number of usable beats in a given stability window. The stability window with the highest number of such usable beats would be assigned the lowest (best) rank. In one embodiment, the weighting coefficient variables M, N, 0, and P may be assigned the values 3, 3, 1, and 1, respectively. Any other value including 0 may be assigned to any of the weighting coefficients at the discretion of the user. Once the above formula is applied and ranks are calculated, in one embodiment, the system is configured to select the three non-overlapping (meaning that the extraction windows to not overlap) windows having the highest such formula based ranks (i.e., the lowest sum of the ranks)—and use such data for extraction (42), and subsequent statistical analysis (44).
In an alternative embodiment, all usable beats in a given scanning window (such as all 600 seconds of the scanning window 26 of
Selection Rank=absolute value of (QTmean[extraction candidate]−QTmean[scanning window])+absolute value of (QTmean[extraction candidate]−QTmean[scanning window])
As in the aforementioned stability formula, weighting coefficients may be assigned to both terms of the above Selection Rank formula. Using this formula, all 10 second (or whatever time period is selected) extraction candidates may be ranked, and the top three (or whatever selected representative number) non-overlapping rank values (i.e., with the lowest calculated selection rank values) may be chosen to be the representative ECG data for subsequent statistical analysis, as in the last two steps of the embodiment described in reference to
In practice, the techniques described in reference to
Referring to
While multiple embodiments and variations of the many aspects of the invention have been disclosed and described herein, such disclosure is provided for purposes of illustration only. For example, wherein methods and steps described above indicate certain events occurring in certain order, those of ordinary skill in the art having the benefit of this disclosure would recognize that the ordering of certain steps may be modified and that such modifications are in accordance with the variations of this invention. Additionally, certain of the steps may be performed concurrently in a parallel process when possible, as well as performed sequentially. Accordingly, embodiments are intended to exemplify alternatives, modifications, and equivalents that may fall within the scope of the claims.